Kevan Herold
Affiliations: | Yale University, New Haven, CT |
Area:
Medicine and Surgery, Cell BiologyGoogle:
"Kevan Herold"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Abdel-Karim TR, Hodges JS, Herold KC, et al. (2024) Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients. Transplant International : Official Journal of the European Society For Organ Transplantation. 37: 12320 |
| Latres E, Greenbaum CJ, Oyaski ML, et al. (2024) Evidence for C-peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes. Diabetes |
| Russell WE, Moore DJ, Herold KC. (2023) Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013. Diabetes Care. 46: e210-e211 |
| Ramos EL, Dayan CM, Chatenoud L, et al. (2023) Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. The New England Journal of Medicine |
| Libman I, Bingley PJ, Becker D, et al. (2023) Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care |
| Sims EK, Geyer SM, Long SA, et al. (2023) High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment. Diabetologia |
| Herold KC, Gitelman SE, Gottlieb PA, et al. (2023) Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function. Diabetes Care |
| Delgado AL, Preston-Hurlburt P, Lim N, et al. (2023) Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes. Medrxiv : the Preprint Server For Health Sciences |
| Russell WE, Bundy BN, Anderson MS, et al. (2023) Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care |
| Caulfield JI, Aizenbud L, Perdigoto AL, et al. (2023) Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors. Journal For Immunotherapy of Cancer. 11 |